Atara's $31m Pierre Fabre milestone rides on FDA verdict on tab-cel by 31 March
The FDA has accepted Atara's refiled tab-cel application for EBV+ PTLD, but the company reported only $9.9m in cash, which it says lasts into mid-2027.
Atara Biotherapeutics has set out the commercial stakes for tabelecleucel, its cell therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The US regulator has accepted the company's refiled biologics licence application and will give its decision by 31 March 2027. Atara disclosed this with its third-quarter 2026 results.
The FDA has designated the refiling a Class 2 resubmission. As general context, this is the longer of the two review tracks for applications returned after a complete response letter, with a six-month review goal. The company's filing is therefore now on a fixed timetable.
Approval would carry direct financial weight. Atara says it would receive a $31 million milestone payment from its partner Pierre Fabre. The facts available do not give further terms of the agreement, so the wider deal value is not covered here.
The balance sheet adds pressure to the timetable. Atara reported $9.9 million in cash at 30 September 2026 and expects that to fund operations into mid-2027, only a few months beyond the FDA's decision date.
Why it matters
- 31 March 2027 is the FDA decision date for tab-cel in EBV+ PTLD, a useful marker for teams tracking cell therapies in post-transplant conditions.
- A $31 million milestone from Pierre Fabre depends on approval, so the outcome matters commercially to both companies.
- Atara's $9.9 million cash position, guided to last into mid-2027, leaves a narrow gap after the decision date, which is relevant to anyone assessing programme continuity.
Company's press release (SEC filing): Atara Biotherapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Helus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
IM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel
FDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapy
Quantum Biopharma narrows nine-month net loss to $17.3M as cash and digital assets rise
Candel delays prostate cancer BLA to mid-2027 as it refines assay with FDA
